ÂÜÀòÂÒÂ×

Kathy Biberstein has extensive legal, policy and operations expertise in the global biopharma industry, most recently serving as Executive Vice President, Chief Administrative & Legal Officer, Chief Compliance & Risk Officer and Board Secretary at Alkermes plc. Kathy held several senior legal positions prior to joining Alkermes in 2003, including General Counsel and member of the Executive Committee at Serono in Geneva, Switzerland from 1993 to 2000, where she built a worldwide legal department. Just prior to joining Alkermes, Kathy was Of Counsel at Crowell & Moring LLC, and earlier in her career, she was a member of the Executive Board of the World Economic Forum. Kathy currently serves as an observer on the Investment Committees of the UBS Oncology Impact Fund and Oncology Impact Fund 2 and on the Biopharma Advisory Team of FocusMaine. Kathy received a Bachelor of Science degree from Kettering University and a Juris Doctor from the University of Michigan Law School.